01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
May 11, 2022 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
May 09, 2022 16:01 ET | Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET | Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
April 13, 2022 08:00 ET | Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
February 22, 2022 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Announces Management Team Appointments
December 02, 2021 07:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference
November 24, 2021 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 03, 2021 07:00 ET | Praxis Precision Medicines, Inc.
Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study PRAX-114 Phase 2 studies in post-traumatic...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021
October 22, 2021 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference
September 01, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...